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The angiogenic capability of colorectal carcinomas (CRC), and their susceptibility to anti-
angiogenic therapy, is determined by expression of vascular endothelial growth factor
(VEGF) isoforms. The intracellular protein T-cell Intracellular Antigen (TIA-1) alters post-
transcriptional RNA processing and binds VEGF-A mRNA. We therefore tested the hypoth-
esis that TIA-1 could regulate VEGF-A isoform expression in colorectal cancers. TIA-1 and
VEGF-A isoform expression was measured in colorectal cancers and cell lines. We discov-
ered that an endogenous splice variant of TIA-1 encoding a truncated protein, short TIA-1
(sTIA-1) was expressed in CRC tissues and invasive K-Ras mutant colon cancer cells and
tissues but not in adenoma cell lines. sTIA-1 was more highly expressed in CRC than in
normal tissues and increased with tumour stage. Knockdown of sTIA-1 or over-
expression of full length TIA-1 (flTIA-1) induced expression of the anti-angiogenic VEGF
isoform VEGF-A165b. Whereas flTIA-1 selectively bound VEGF-A165 mRNA and increased
translation of VEGF-A165b, sTIA-1 prevented this binding. In nude mice, xenografted colon
cancer cells over-expressing flTIA-1 formed smaller, less vascular tumours than those ex-
pressing sTIA-1, but flTIA-1 expression inhibited the effect of anti-VEGF antibodies. These
results indicate that alternative splicing of an RNA binding protein can regulate isoformarch Laboratories, Veterinary Sciences Building, School of Physiology and Pharmacology,
l BS2 8EJ, UK.
.ac.uk (D.O. Bates).
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file of colorectal cancer and their resistance to anti-angiogenic therapy.
ª 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction cell line, HeLa, prostate cancer cells, PC3 and LNCaP (ATCC;Alternative RNA splicing, export and translational regulation
all contribute to cancer formation and progression
(Venables, 2006). These are dependent on the complex sec-
ondary structure of the 30 UTR of the mRNA recognised by
binding proteins such as T-cell Intracellular Antigen-1 (TIA-
1) (Eberhardt et al., 2007). TIA-1 contains three domains with
RNA recognition motifs (RRM1, RRM2 and RRM3), the latter
two of which have been shown to be important for RNA bind-
ing and selectivity (Bauer et al., 2012) (Cruz-Gallardo et al.,
2014). It has been shown to be alternatively spliced in exon 5
to form two isoforms (a and b, Supplementary Figure 1A)
with b being the most active in its splicing activity, but TIA-1
also acts as a stress induced translational inhibitor, localising
to stress granules with polyA RNA (Izquierdo and Valcarcel,
2007). TIA-1 alters both co-transcriptional and post-
transcriptional RNA processing and binds VEGF-A RNA
(Suswam et al., 2005), the alternative splicing of which influ-
ences the angiogenic capability of colorectal carcinomas
(CRC) (Ferrara et al., 1991).
VEGF-A exists as multiple alternatively spliced isoforms.
Exons 6 and 7 endow heparin binding (Houck et al., 1991),
whereas exon 8 determines angiogenicity (Harper and Bates,
2008). Exon 8 has two splice acceptor sites, a proximal one,
and a distal one, 66 bases downstream. The stop codon for
the two isoforms lies the same number of bases downstream
from the respective splice sites, resulting in two families of
isoforms of the same amino acid number but with differing
six amino acid sequence at the end, which alter the angioge-
nicity of the protein. Proximal splice site (PSS) selection in
exon 8 results in the angiogenic family (VEGF-Axxx where
xxx is the number of amino acid e.g. VEGF-A165), but distal
splicing (DSS) results in VEGF-Axxxb, anti-angiogenic proteins
of the same size (e.g. VEGF-A165b) (Bates et al., 2002). A variable
but specific upregulation of the angiogenic isoforms is seen in
colorectal cancer (Varey et al., 2008), but although the mecha-
nisms underlying this splice specificity are being elucidated in
epithelial cells (Amin et al., 2011; Nowak et al., 2008) and lung
cancer (Merdzhanova et al., 2010), isoform specific control of
expression, particularly in colon cancer is still not known.
We therefore tested the hypothesis that TIA-1 could regulate
VEGF splicing.2. Materials and methods
2.1. Cells and tissues
HEK293, colonic carcinoma cell lines HT29, HCT116, HAC7,
SW480, Osteosarcoma SaOS-2 and U2OS, the cervical cancerRockville, MD) LS174t (ECACC, Salisbury, UK), adenoma cell
lines AA/C1 and RG/C2, the in vitro transformed adenoma
cell line AA/C1/SB/10, referred to as 10C cells) and breast can-
cer MDA-MB231 (Caliper, PerkinElmer, USA), HumanHaeman-
gioma Endothelial Cells (ESC and stem cells (HSC, a kind gift
from Joyce Bischoff at Harvard University), myeloma RPMI-
8226, and cardiac myocytes (HCM, from Promocell) were
maintained as described previously (Williams et al., 1990) or
according to manufacturer’s instructions. Cancer cell lines
were validated by STR profiling (Identicell, Aarhus, Denmark).
Human tissues were collected under Local Ethics Committee
Approval. An initial study was undertaken on six frozen
paired colon samples (normal and cancerous) from partial co-
lon resection. Additional RNA was extracted from 40 formalin
fixed, paraffin embedded (FFPE) samples of normal and
tumour tissues. These were taken from 22male, 18 female pa-
tients, mean age 69 years, 28 with colon carcinoma, 18 with
rectal carcinoma and 1 with carcinoma of the rectosigmoid
junction.
2.2. Antibody generation
An antibody to sTIA-1was generated by Abgent Europe using a
KLH-conjugated VSLKNGQ NCPG peptide. For access please
contact the corresponding author.
2.3. Protein analysis
Cell experiments used at least 3 independent biological repli-
cates (independent experiments), with each western blot,
ELISA and RT-PCR carried out on independently replicated
samples. For western blot, and RT-PCR where gels are shown,
each is indicative of a representative of 3 experiments, and
quantitated as per the figures. ELISAs were undertaken on 3
separate sets of cells. Protein samples from homogenised tis-
sue (100 mg) and whole cell extract (50 mg) were prepared using
standard protocols. Protein lysates were resolved on SDS
PAGE, and probed with a mouse monoclonal anti-COX-2 anti-
body (sc-19999; Santa Cruz), a/b-tubulin (Sigma) anti-VEGF-
A165b IgG (A56/1; R&D Systems), rabbit polyclonal anti-TIA-1
antibody (sc-28237; Santa Cruz, detects full length and sTIA-
1 isoforms), or sc-166246 C10 mouse monoclonal N-terminal;
Santa Cruz and rabbit anti-VEGF-A IgG (A-20, sc-120; Santa
Cruz), goat polyclonal laminin (Santa Cruz) and mouse mono-
clonal lamin (Cell Signalling) antibodies. Proteins were
detected using chemiluminescence and analysed by NIH im-
age, or by fluorescently labelled secondary antibody imaging
and imaged using a LiCOR Odyssey, and quantified using
LiCOR imaging software. ELISAs were carried out as described
previously (Varey et al., 2008). The VEGF-A165b ELISA uses an
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Axxx isoforms, but its affinity to all of the different VEGF-Axxxb
isoforms is not known.Wehave assumed that it is the same as
VEGF-A165b and therefore calculated the levels making this
assumption.
2.4. VEGF immunoprecipitation and mass spectrometry
For immunoprecipitation, 50 ml of protein A or protein G
(depending on capture antibody) magnetic beads (Millipore)
was washed with 500 ml PBS containing 0.1% Tween 20. After
removing the buffer, the beads were resuspended in 100 ml
of PBS/0.1% Tween, capture antibody added to the beads and
incubated at room temperature for 10 min before adding the
protein samples. The protein samples and antibody were
incubated at 2e8 C overnight with continuous mixing,
washed with PBS/Tween0.1% before adding sample buffer.
For spectrometry, after running the samples on PAGE, the
gel was fixed in methanol:acetic acid (50%:7%) for 30 min
and stained with SYPRO Ruby (Molecular Probes) overnight.
The gel was de-stained in methanol:Acetic Acid (10%:7%),
washed and imaged. The band was excised and subjected to
in-gel tryptic digestion using a ProGest automated digestion
unit (Digilab UK). The resulting peptides were fractionated us-
ing a Dionex Ultimate 3000 nanoHPLC system in line with an
LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific)
as described in the supplementary material. Raw data files
were processed and quantified using Proteome Discoverer
software v1.2 (Thermo Scientific) and searched against the
SwissProt Human database using the Mascot search engine
(Matrix Science) with parameters as described in the supple-
mentary material.
2.5. RNA analysis
Total RNAs from tissue (200 mg) and cells (107) was extracted
using the RNeasy kit (Qiagen) and quantified. RNA was
extracted from 25 mm thick sections of the FFPE samples by
RNeasy FFPE kit (Qiagen) according to themanufacturer’s pro-
tocol. Standard RT-PCR protocolswere used. For cDNA synthe-
sis form FFPE samples random primer or gene specific primers
were used. Extracted DNA was cloned into the p-GEM T-Easy
plasmid (Promega) and sequenced using standard synthetic
primers complementary to the vector DNA at the junction of
the cloning site (T7, SP6) and a pTarget sequencing primer
50-TTACGCCAAGTTATTTAGGTGACA-30 by the Dundee
sequencing service (Dundee University). For each cell line 10
clones were sequenced.
RNA Immunoprecipitation RIP was performed as previ-
ously described (Cok et al., 2003; Tenenbaum et al., 2002). In
brief, 5  107 cells were harvested, cross linked with 1%form-
aldehyde at room temperature for 10 min and quenched with
0.25 M glycine. Protein was extracted, and 100 mg of pre-
cleared protein incubated with 3 mg TIA-1 antibody immobi-
lized using Seize Primary immunoprecipitation kit (Pierce
Biotechnology) and immunoprecipitates isolated by centrifu-
gation. Total RNA was extracted from immunoprecipitates
and subjected to RT-PCR as described.2.6. MS2-MBP binding experiments
The VEGF-A sequence from 35 bp upstream of exon 8a to 35 bp
downstream of exon 8b was inserted into the ADML-MS2
plasmid as previously described (Nowak et al., 2008). Nuclear
protein (75 mg) from HEK 293 or AA/C1/SB/10 (10C) cells were
prepared and added to the MS2-MBP fusion protein/VEGF-
RNA mix in 0.5 mM ATP, 6.4 mMMgCl2, 20 mM creatine phos-
phate for 1 h at 30 C. Proteins bound to the MS2-MBP/VEGF-
MS2 RNA complex were affinity selected on amylose beads
and immunoblot analysis was performed on 30 mg of protein
samples using TIA-1 antibody and b-tubulin antibodies as pre-
viously described (Nowak et al., 2008). Blots are representative
of at least three experiments.
2.7. TIA-1 construct and cell transfection
The cDNA for flTIA-1was generated by RT-PCR amplification
using Pfu Turbo DNA polymerase (Stratagene) and primer
TIA-1-forward and TIA-1-reverse from RNA from the RG/C2
adenoma cell line. The 1239 bp fragment was cloned in p-
GEM T-easy vector and sequenced in both directions. The
cDNA for both variants (13-exon TIA-1NCBI NM_022173.2
and 12-exon TIA-1NCBI NM_022037.2) were obtained using
these primers. For in vitro expression, the cDNA were subcl-
oned into mammalian expression vectors, pTarget (Promega)
and pcDNA3 according to the manufacturer’s instructions.
siRNA to exon 6A was generated by Qiagene. Two custom siR-
NAs targeting sTIA-1 (siRNA1: CAGAATTGCCCTGGCTAACTA
and siRNA2: GCCCTGGCTAA CTACAAGCTA) and control
siRNA (Lopez de Silanes et al., 2005) were assessed. Two colon
cancer cell lineswere transfectedwithmixture of the 2 siRNAs
(50 nM) using HiPerfect transfection reagents (Qiagen). Knock-
down was monitored after 24 (RNA) and 48 (protein) hours.
TIA-GFP plasmid is a kind gift from Paul Anderson (Harvard).
Transfection: LS174t and 10C cells were electroporated
with 2 mg cDNA of pTarget-flTIA-1 cDNA in pTarget and
pmaxGFP vectors pTarget vector or pmaxGFP with an
AMAXA Nucleofector system using a basic epithelial cell
transfection Kit (VPI-1005, Amaxa GmbH). Transfectants
were analysed 24 h post nucleofection by Trypan blue staining
and fluorescence microscopy for GFP control plasmid. Trans-
fected cells were selected using G418 (500 mg/ml) for 4 weeks.
2.8. Immunofluorescence
The cells were 4% formaldehyde fixed (15 min) and incubated
in 1%BSA/10% normal goat serum in TBS-Tween (0.1%) for 1 h.
The cells were then incubated with the antibody (ab40693 rab-
bit polyclonal C-terminal, or sc-166246 C10mousemonoclonal
N-terminal, 5 mg/ml) overnight at þ4 C. The secondary anti-
body (red) was Alexa Fluor donkey anti-rabbit and (green)
Alexa Fluor 488, used at a 1/500 dilution for 1 h. Vector shield
Hoescht was used to stain the cell nuclei (blue). For confocal
imaging a Nikon D-Eclipse C1 Laser Scanning Microscope
was used. Cells were imaged using a 60 oil immersion objec-
tive with a numerical aperture (NA) of 1.4e5 cell clumps were
selected at random and a z stack of 25 images taken for each
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selected and used for the analysis of the ratio of staining be-
tween the nucleus (Hoescht) and cytoplasmic regions of the
cell. In NIH image, the TIA-1 positive area and the Hoescht
positive area were determined by tracing and nuclear area
subtracted from the TIA-1 positive area and expressed as a
proportion of the TIA-1 positive area.
2.9. Luciferase reporters
The VEGF-A full length 30UTR was cloned downstream of the
Thymidine Kinase promoter and the Firefly Luciferase ORF
(construct LUC-VEGF165), (from Jean-Jacques Feige and Nadia
Cherradi, CEA Grenoble). This was modified using the Quick-
Change II XL Site-Directed Mutagenesis Kit (Stratagene) to
delete the first 66 nucleotides (LUC-VEGF-A165b) of exon 8.
The plasmid pRL-TK (Promega) encoding Renilla Luciferase
was used as an internal control. 10C cells were transfected
with the both reporter constructs using the Amaxa system.
Luciferase activities were measured with the DUAL-
Luciferase reporter assay system (Promega) on a VICTOR 3
1420 Multilabel Counter Luminometer (PerkinElmer).
2.10. Actinomycin experiments
VEGF-AmRNAdecaywasmeasured in 10C cells after transfec-
tion with TIA-1 and treatment with 10 mmol/L actinomycin D.
Cells were harvested every hour over a 4-h period, and VEGF-A
isoform mRNA levels analysed by RT-PCR.
2.11. Tumour growth in nude mice
Experiments were undertaken under home office license after
review by theUniversity of Bristol Ethical review group. 2 106
untransfected, flTIA-1, VEGF-A165, doubly or vector transfected
cells in 0.2ml PBSwere injected subcutaneously in the dorsum
of 6 Balb/C nude mice (from University of Bristol colony) for
each group. Mice were treated bi weekly with mouse IgG
(Sigma), or an anti-mouse VEGF-A neutralising antibody
(Liang et al., 2006) intraperitoneally twice weekly at 2 mg/kg.
Sample sizewas calculated a priori using G-Power on the basis
of being able to have 80% power to detect a mean  SD 2  0.5
fold change in size and vascular density. All experimentswere
carried out with the investigator blinded to the groups.
2.12. Immunohistochemistry
5 mm thick de-waxed, re-hydrated sections were microwaved
in 0.01 M sodium citrate, pH 6.0 for 15 min at 800 W. Sections
were incubated with VEGF-A Receptor 2 (Rabbit Mab 2479 Cell
Signalling) or CD31 antibodies at 1:100 overnight at 4 C in a
humidity chamber and after application of secondary anti-
bodies and appropriate enzymatic process (Vector DAB kit),
vessel number counted in 10 randomly selected areas for
each tumour (n ¼ 6).
2.13. Statistical analysis
Results were analysed using Prism software, given as
Mean  SEM unless otherwise stated and compared usingone-way ANOVA or t tests for comparison of means. Propor-
tions were compared using Fisher’s exact test. p < 0.05 was
considered significant. Power analysis on non-significant re-
sults were carried out to ensure power of at least 80% (using
G-Power).3. Results
3.1. Ras mutant cancer cells express a novel splice
variant of TIA-1
In five carcinoma (LS174t, HCT116, SW480, HT29, HCA7) and
an adenocarcinoma line (10C) TIA-1 RNA, but not two other
RNA binding proteins, TTP and HuR, was lower than in ade-
noma lines RG/C2, and AA/C1 (Figure S1A, B), amplified us-
ing primers to detect full length (flTIA-1). Expression of the
42e43 kDa TIA-1 protein was similar across cell lines, but
in all carcinoma and the 10C cells, an additional band at
w16 kDa was seen (Figure 1A, Figure S1C) suggesting the
presence of a truncated TIA-1 protein. Amplification of
TIA-1 mRNA sequence from the 10C cells using primers
that flank exons 6 and 7 revealed an additional product
only in carcinoma and 10C cells (Figure 1B, Figure S1D),
due to the insertion of a 66bp sequence (Figure 1C) from
the intron between exons 6 and 7 of the tia-1 gene
(Figure 1E). This was also present in BRAF V600E þ ve A375
melanoma cells (Figure S1E). The 66base sequence is flanked
by a classical consensus splice sequence (AG.GU) and has a
73% CU sequence immediately upstream, suggesting a
cassette exon undergoing alternative splicing. This
sequence results in a unique 11 amino acid sequence and
a premature stop codon, which should generate a 144 amino
acid truncated TIA-1 peptide of 15.8 kDa (Figure 1D), with
only RNA recognition motif (RRM)-1 and part of the RRM 2,
consistent with the short band (w16 kDa) detected by the
anti-TIA-1 antibody in Figure 1A. Sequencing of TIA-1
genomic DNA from 10C cells showed no mutations in the re-
gion around either the 50 or 30 acceptor or donor sites. This
mRNA is identical to a splicing event described as exon 6A
when TIA-1 itself was over-expressed in a cancer cell line
(Le Guiner et al., 2001), but its endogenous expression has
not previously been demonstrated. A BLAST search of this
sequence showed identity in 66 ESTs, all consistent with it
being this TIA-1 isoform. A rabbit antibody raised to the
unique peptide sequence of sTIA-1 detected the protein in
10C cells (Figure S1F). Immunoprecipitation of 10C protein
(Figure S1G) and immunoblotting for TIA-1 showed both
short and full length TIA-1. IP with a flTIA-1 antibody and
IB with sTIA-1 demonstrated that the protein detected
with this antibody was TIA-1 in LS174t cells as well. This
protein was not present in AAC1 cells. (Figure S1H). Both
protein (Figure 1E top image) and RNA expression
(Figure 1E bottom image) of sTIA-1 was seen in sarcoma
(SaOS), HeLa, prostate cancer (PC3 and LNCaP), and MDA-
MB-231 breast cancer cells, but not osteosarcoma (U2OS),
haemangioma endothelial (a differentiated phenotype), hae-
mangioma stem (HSC), human embryonic kidney (HEK), or
RPMI-8226 leukaemia cells or human cardiac myocytes
Figure 1 e TIA-1 splicing is modified in colon carcinoma cells. A. Immunoblot for TIA-1 in carcinoma, adenocarcinoma and adenoma cell lines.
A smaller protein product (sTIA-1) was seen in carcinoma and adenocarcinoma (AC) cells. B. RT-PCR for TIA-1 using exon 6/7 spanning
primers revealed two splice variants in LS174t, HCA7 and 10C cells. -RT [ RNA without reverse transcriptase. C. Exon/intron structure,
position of primers and sequence of exon 6a of TIA-1. D. Protein sequence of the translated mRNA product. Underlined section is unique to
sTIA-1. E. Western blot and PCR for sTIA-1 of multiple cell lines. 10C-adenocarcinoma, LS174t colon carcinoma, AA e adenoma, SaOS-
sarcoma osteogenic2, U2OS e osteosarcoma, HEC e haemangioma endothelial cells, HSC e haemangioma stem cells, HeLa e ovarian
carcinoma, LNCaP e prostate cancer lymph node metastasis, PC3 prostate cancer, RPMI e RPMI8266 myeloma cells, MDA-MB-231 breast
cancer cells, HCM-human cardiac myocytes. F. LS174t (K-ras activating mutation heterozygous) and 10C (K-ras homozygous) were treated with
increasing concentrations of the Ras inhibitor FTA and subjected to RT-PCR for TIA-1. Ras inhibition prevented splicing of sTIA-1.
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only 2 of the 8 that lacked sTIA-1 have ras mutations or
over-expression, whereas 8 of the 10 that did express
sTIA-1 had ras over-expression or activating mutations,
and the other two are BRAF mutants, (HT29 and
A375 cells). In both LS174t and 10C cells the Ras inhibitor
Farnesyl Thiosalysilic Acid (FTA) significantly inhibited
splicing to sTIA-1 in a dose dependent manner (Figure 1F).
Downstream signalling through MEK and PI3K was required
for this splicing in both cell lines (Figure S2A). Ras is active in
AAC1 and RGC2 cell lines (sTIA-1 negative) indicating that it
is necessary, but not sufficient to induce splicing of TIA-1.3.2. TIA-1 variants differentially regulate VEGF isoform
expression
Ras inhibition (Figure 2A, Figure S2BeD) and MEK and PI3K in-
hibition (Figure S2E) also switched splice form expression
from VEGF-A165a to VEGF-A165b in both 10C and LS174t cell
types. VEGF-A165b protein expression was confirmed by
immunoprecipitation and peptide sequencing (Figure S3A
and B). These results suggest that hyperactivated ras signal-
ling also acts to repress VEGF-Axxxb splicing, so we investi-
gated a possible link between VEGF and TIA-1. Isoform
specific siRNA knockdown of sTIA-1 (Figure S3CeG), reduced
Figure 2 e TIA-1 regulates VEGF splice form expression. A. PCR for VEGF-A showing ras inhibition by FTA increased VEGF-A165b expression.
B. Colonic tumour cells were transfected with 2 siRNAs targeted to exon 6A of TIA-1 (sTIA), or scrambled siRNAs (Ctrl), and RNA extracted,
reverse transcribed and subjected to PCR for VEGF-A isoforms. Plasmids containing VEGF-A165a or VEGF-A165b were used as positive controls.
C. Protein was extracted from such transfected cells, quantitated and subjected to ELISA for VEGF-Axxxb and total VEGF. VEGF-Axxxa levels
were calculated from the difference between total and VEGF-Axxxb. D. Percent of total VEGF-A that is VEGF-Axxxb found in LS174t or 10C cells
after siRNA knockdown of sTIA-1, measured by ELISA. E. Untransfected cells, or cells transfected with pcDNA3 control (vector) or flTIA-1
expression vector had mRNA extracted and were subjected to RT-PCR using primers that detect both proximal (PSS, VEGF-A165a) and distal
spliced isoforms (DSS, VEGF-A165b). F. Protein extracted from cells treated in this way was subjected to SDS PAGE and immunoblotted with an
antibody to VEGF-A165b, TIA-1 or tubulin (loading control). G. Protein was subjected to ELISA for pan-VEGF-A and VEGF-A165b. The
percent of total VEGF-A that is VEGF-A165b is shown. ND- [ Not determined. See also Figure S2. H. Cells were lysed, and part of the lysate
cross linked, and precipitated with an antibody to TIA-1 (D), and the remainder (L) subjected to RNA extraction. After IP the RNA was
extracted from the precipitate and both RNA samples subjected to reverse transcription and PCR for VEGF-A isoforms. Adenoma but not
carcinoma cell VEGF-A165 RNA was precipitated by TIA-1 antibody. I. flTIA-1 transfected and untransfected colon tumour (10C or LS174t) cells
were crosslinked, immunoprecipitated with TIA-1 antibody, RNA extracted and subjected to RT-PCR for VEGF. cDNA from cells without
immunoprecipitation (no IP) was also subjected to RT-PCR for VEGF. Lack of binding of VEGF-A165 RNA to TIA-1 in sTIA-1 expressing cells
was rescued by flTIA-1 over-expression. J, Constructs in vitro transcribed and used to investigate mRNA binding of TIA-1. Nuclear extract (NE)
of HEK293 cells (left) or 10C (right) was incubated with in vitro transcribed mRNA constructs A, B or C, and run over an MS2-MBP binding
column. Bound protein, and unbound (flow through) was run on SDS PAGE and immunoblotted for TIA-1. ORF [ Open Reading Frame.
** [ p< 0.01, * [ p< 0.05 compared with ctrl. One-way ANOVA. Post hoc Bonferroni test.
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VEGF-A165b mRNA in 10C cells but made no difference in
AA/C1 cells (Figure 2B). VEGF-A165b but not VEGF-A165 protein
was significantly increased by siRNA to sTIA-1 in LS174t cells
( p ¼ 0.013), whereas only a significant reduction in the
VEGF-A165a isoform expression was seen in 10C cells
( p ¼ 0.03, Figure 2C). Thus there was a significant switch in
the ratio of isoforms in both cell types towards a less angio-
genic phenotype after knockdown of sTIA-1 (Figure 2D,Figure 3 e TIA-1 localisation regulates VEGF-A mRNA translation but n
treated with the transcriptional inhibitor Actinomycin D (ActD) followed
measured with image analysis and the degradation rate determined by expo
VEGF-A165b mRNA in the presence or absence of flTIA-1. D. VEGF-A 3
Luciferase/Renilla reporter gene This was then transfected into 10C and L
Luciferase and Renilla were measured in these cells. ***[ p< 0.001, **[
VEGF-A165b was seen when flTIA-1 was transfected. G Protein was extract
mutant), fractionated into nuclear and cytoplasmic fractions, and subjected
nucleus in AAC1 cells, but in both nucleus and cytoplasm in sTIA-1 expr
(endogenously express both sTIA-1 and flTIA-1) were transfected with TIA
imaged by confocal microscopy. The proportion of GFP outside the Hoesch
nucleus as a proportion of the total staining area from a single confocal slic
sTIA-1 or scrambled siRNA, and stained for endogenous TIA-1 with an ant
was calculated. * [ p< 0.05 compared with scrambled. J. 10C cells were
protein. The intensity of the expression in the cytoplasm and the nucleus wap < 0.01 ANOVA). Conversely, VEGF-A165b expression was
rescued by flTIA-1 expression in 10C and LS174t cells
measured by RT-PCR (Figure 3E), immunoblot (Figure 2F) and
ELISA (Figure 2G), in 10C cells to 90% VEGF-A165b ( p < 0.001
compared with ctrl), similar to AA/C1 cells and in LS174t
from 5  1.8% to 12  1.5% of total VEGF-A ( p < 0.01). The
reverse experiment (over-expression of sTIA-1) resulted in
lethality of unknown cause. flTIA-1 also reduced
cyclooxygenase-2 protein expression (Figure S3H), a knownot degradation. A. 10C cells, or 10C cells expressing flTIA-1 were
by RT-PCR for VEGF. B. The intensity of the PCR product was
nential curve fit (bottom graphs). C. Half-life of VEGF-A165a and
0UTR constructs were generated downstream of firefly luciferase in a
S174t in the absence (E) or presence (F) of flTIA-1 over-expression.
p< 0.01. NS[ Not significant Repression of VEGF-A165 relative to
ed from AAC1 (K-ras wild type) and 10C and LS174t cells (both K-ras
to immunoblotting. TIA-1 expression was found predominantly in the
essing cells. H. AAC1 (endogenously express flTIA-1) and 10C cells
-1-GFP construct. Nuclei were stained with Hoescht and cells were
t staining (arrow) was calculated from the area of staining outside the
e through the nucleus (slice). I. Cells were transfected with siRNA to
ibody to the N terminus. The proportion of TIA-1 that as cytoplasmic
transfected with scrambled or sTIA-1 siRNA and flTIA-GFP fusion
s determined. **[ p< 0.01 compared with scrambled unpaired t test.
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that, whereas 10C, AA/C1 and RG/C1 all expressed both VEGF-
A165 and VEGF-A165b, immunoprecipitation with an anti-TIA-1
antibody pulled down only VEGF-A165 in AA/C1 and RG/C1
(cells expressing only flTIA-1), but no VEGF-A mRNA in sTIA-
1 expressing cell lines (10C, HCA7 and LS174t, Figure 2H). In
10C and LS174t cells, transfection with flTIA-1 restored TIA-1
binding to VEGF-A165a mRNA, as evidenced by pull down of
VEGF-A165 mRNA, compared with untransfected cells (ctrl,
Figure 2I). sTIA-1 also affected binding of TIA-1 to COX-2
(Figure S3I). The binding site of TIA-1 to VEGF-A mRNA was
demonstrated, in HEK cell nuclear extract using an MS2-MBP
binding assay (Nowak et al., 2008) to reside in the VEGF-A
exon 8a sequence and 35 bases of intron 7 (Figure 2J). Nuclear
extract from 10C cells, while containing TIA-1 (as seen in the
flow through unbound eluate in the lower panel), was unable
to bind to VEGF-A mRNA sequences (Figure 2J).
flTIA-1 has been shown to function both as a translational
repressor (Piecyk et al., 2000) and an alternative splicing factor
(Barron and Lou, 2012; Del Gatto-Konczak et al., 2000). Expres-
sion of flTIA-1 did not affect the half-lives of VEGF-A165b and
VEGF-A165 mRNA in 10C cells, determined by investigating
mRNA decay rates in cells treated with the transcriptional in-
hibitor Actinomycin D (ActD) (Figure 3A and B). Although it did
increase the amount of VEGF-A165b at the start of the experi-
ment, Figure 3C shows that there was no difference in the
half-life. There was no significant difference in expression of
a luciferase reporter containing the 30UTRs of VEGF-A165a or
VEGF-A165b (Figure 3D) in either 10C or LS174t cells
(Figure 3E), but transfection with flTIA-1 resulted in signifi-
cantly increased luciferase activity with the VEGF-A165b
30UTR compared with the VEGF-A165a 30UTR (Figure 3F) indi-
cating preferential translation of VEGF-A165b by TIA-1 as well
as inhibiting splicing of VEGF-A165. The flTIA-1 isoform con-
tains three RNA recognition motifs (RRMs). RRM 2 and 3 are
required for 30 translational repression (Bauer et al., 2012),
and this is lacking in sTIA-1, which only contains the full
length RRM1, which cannot by itself bind to RNA (Dember
et al., 1996) but is required for flTIA-1 binding to specific se-
quences (e.g. U rich sequences) (Bauer et al., 2012), thus
conferring specificity. Thus, while sTIA-1 prevents flTIA-1
mediated repression of splicing of the pro-angiogenic iso-
forms of VEGF-A, the increased level of VEGF-A165b mRNA
and protein induced by over-expression of flTIA-1 in colon
cells suggest that it also acts to selectively represses transla-
tion of the exon 8a containing isoforms. This may explain
why the effects of sTIA-1 siRNA knockdown on RNA and pro-
tein were subtly different in the two cell types (in 10C it
increased VEGF-A165b RNA but not protein, and vice versa in
LS174t cells).
3.3. sTIA-1 alters nuclear localisation of flTIA-1
Nuclear/cytoplasmic separation of proteins (Figure S4A)
showed that in AAC1 cells, TIA-1 is found as the full length
form but only in the nucleus, whereas in LS174t and 10C cells
a substantial proportion of all TIA-1 isoforms and products
were expressed in the cytoplasm, including sTIA-1
(Figure 3G). This was confirmed by transfection of cells with
full length TIA-1 fused to GFP (Figure 3H), and byimmunofluorescent staining with antibodies to the N termi-
nus of TIA-1 (detects all isoforms, Figure S4B). sTIA-1 knock-
down, surprisingly, resulted in enhanced cytoplasmic staining
for TIA-1 (Figure 3I). This was confirmed in flTIA-1-GFP over-
expressing 10C cells, with sTIA-1 knockdown (Figure S4C).
N-terminal staining (whichwould detect sTIA-1) was reduced,
consistent with a reduction in only the sTIA-1 component
(Figure S4C). Nuclear localisation of GFP-flTIA-1 was reduced
by sTIA-1 knockdown (Figure 3J). sTIA-1 therefore alters local-
isation of the flTIA-1 within the cell, thereby preventing it
from binding VEGF-A mRNA. The increased not decreased
cytoplasmic TIA-1 resulting from reduced of sTIA-1 in K-Ras
mutant cells suggests that the GFP-flTIA-1 fusion protein
localisation is sTIA-1 dependent. Thus sTIA-1 expression in
K-Rasmutant cells may act by preventing flTIA-1 nuclear traf-
ficking (to and from the nucleus), preventing it from interact-
ing with other potential regulators of splicing and/or
translation. This in turn alters the expression of VEGF-A iso-
forms and results in a more angiogenic phenotype of the tu-
mours. Co-immunoprecipitation indicated that it is possible
that the two isoforms could complex together (Figure S1G),
but how this happens is not clear. The localisation experi-
ments indicate that in carcinoma cells flTIA-1 excess either
by over-expression with GFP, by knockdown of sTIA-1 or
both results in cytoplasmic flTIA-1 and/or VEGF-A165b expres-
sion, whereas in adenoma cells, where K-Ras is not over-
expressed, flTIA-1 is nuclear. Thus when sTIA-1 dominates
in the nucleus, VEGF-A165 is generated.
3.4. sTIA-1 is expressed in human K-Ras mutant
colorectal tumours
sTIA-1 and VEGF-A165b RNA were detected in freshly isolated
human colorectal cancer samples (Figure 4A) confirmed by
sequencing. Quantification showed both a significant increase
in sTIA-1 expression in cancer (Figure 4B) and a significantly
lower VEGF-A165b:VEGF-A165 ratio in the tumours than the
controls (Figure 4C). In histological samples, flTIA-1 RNA
(Figure 4D) was found only in 13 of 31 tumours (42%) but 22
of 30 normal tissues (73%, p¼ 0.02, Fisher’s exact test) samples
(Figure 4E). The proportion of tumours that were K-Ras
mutant was significantly higher ( p < 0.01) in those that had
no flTIA-1, and K-Ras mutant tumours rarely (2/13 cases)
had flTIA-1 detected (Figure 4F). Quantification showed that
sTIA-1 exceeded flTIA-1 in 20 of 31 tumours (65%) but in
only 9 of 30 normal tissues (30%, p¼ 0.01, Figure 4G). Moreover,
sTIA-1 was present in 14 of the 15 Dukes’ C (93%), but only 9 of
the 16 Dukes’ B (56%, p < 0.01, Figure 4H). There was a signif-
icantly higher microvascular density (Figure 4I) in samples in
which sTIA-1 but not flTIA-1 was found (Figure 4J).
3.5. flTIA-1 over-expression reduces tumour growth and
results in bevacizumab resistance
Over-expression of flTIA-1 inhibited tumour growth in nude
mice (Figure 5A), resulting in significantly smaller tumours
at 18 and 21 days after injection (Figure 5B). This reduction
was rescued by VEGF-A165 cDNA expression i.e. VEGF-A that
was not under the control of alternative splicing (Figure 5B).
Tumours from flTIA-1 transfected cells had reduced tumour
Figure 4 e sTIA-1 splice variants are present in human colon cancer. A. Upper panel, RT-PCR of mRNA extracted from paired tumour (T) and
normal (N) tissues from 6 patients undergoing bowel resection for colon cancer. In 4 of 6 patients, the splice isoform were present in the tumours,
but not in the normal tissue. Lower panel, RT-PCR for splice forms of VEGF. B. Quantitation of band intensity of sTIA-1 relative to flTIA-1 in
control and tumour tissue. C. Quantitation of band intensity of VEGF-A165b relative to VEGF-A165 in colon cancers compared with normal
tissues. D. RNA was extracted from 25 mm thick scrolls of paraffin embedded sections of 40 colorectal carcinoma (20 Duke’s B, 20 Duke’s C stage)
and matched normal (N) samples, and RT-PCR carried out to detect flTIA-1 and sTIA-1. RT-PCR detected TIA-1 RNA expression in 61/80
samples. E. Number of cases in which flTIA-1 was found in tumour or normal ( p[ 0.02 Fishers exact test). F. Number of cases in which flTIA-1
was found (black bars) or not found (white bars) in wildtype versus ras mutant tumours. G. Number of cases in which sTIA-1 was more highly
expressed than flTIA-1 (compared with normal p [ 0.0106). G Number of cases in which sTIA-1 was detectable in Duke’s B compared with
Duke’s C grade ( p[ 0.018, statistics for E, F and G Fisher’s exact test). H. Sections adjacent to those from which RNA had been extracted were
stained for blood vessels (CD31). Blood vessels were counted per high power field, blinded for sTIA-1 status. The gel shows the PCR product for
the two sections shown. Arrows indicate blood vessels. I. Microvascular density for sections where flTIA-1 was more intense than sTIA-1 and vice
versa. * [ p< 0.05 unpaired t test.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 6 7e1 7 8 175vessel density (Figure 5C and D, p < 0.01). Mice with LS174t tu-
mours expressing flTIA-1 treated with an anti-VEGF-A anti-
body (Liang et al., 2006) grew significantly faster compared
with IgG (Figure 5E), at the same rate as wild type tumours
treated with anti-VEGF-A treatment (Figure 5F), but still
more slowly than untreated wild type tumours (Figure 5G).4. Discussion
Here we identify a novel K-ras dependent endogenous splice
variant of TIA-1, short TIA-1 (sTIA-1) in CRC patients and can-
cer cells, which controls VEGF-A isoform expression. This
sTIA-1 had been identified as being capable of being induced
by over-expression of recombinant mouse TIA-1 in human
HEK cells (Le Guiner et al., 2001). This is the first demonstra-
tion that this splice variant may be present in human cancers,
and that it may regulate VEGF splice form expression. sTIA-1,containing only one RNA recognition motif (RRM), prevented
binding of full length TIA-1 to VEGF-A165 mRNA, blocking
both its angiogenic VEGF splice site repression and its promo-
tion of translation of anti-angiogenic VEGF-A165b. It has previ-
ously been shown that RRM2 and 3 are required for binding of
TIA-1 to RNA (Bauer et al., 2012), and interestingly, RRM3 is
required for binding to C rich stretches (Cruz-Gallardo et al.,
2014). Moreover, inclusion of exon 5 in TIA-1 results in a
higher splice activity, indicating that the activity of the protein
can be altered by alternative splicing (Izquierdo and Valcarcel,
2007). As both of these domains are disrupted in sTIA, it is
likely that sTIA-1 does not act by directly binding to the
VEGF RNA and preventing flTIA-1 from exerting its effects,
and the direct mechanism of repression of distal splicing is
not known. As sTIA-1 did co-immunoprecipitate with flTIA-1
it is possible that sTIA-1 acts by heterodimerising with flTIA-
1 and preventing it from repressing splicing and/or translation
of the pro-angiogenic isoform, VEGF-A165a. Cancer cells over-
Figure 5 e flTIA-1 over-expression reduces growth of sTIA-1 expressing tumours in vivo in a VEGF dependent manner A. 2 3 106 control
transfected (vector), flTIA-1 transfected cells or double VEGF-A165a and flTIA-1 transfected LS174t colon carcinoma cells were injected into 6
nude mice per group and tumour volumes measured by callipers. A. Tumours grown in nude mice. B. Mean ± SEM tumour volumes calculated
from the diameters. C. Tumours were stained with CD31 and VEGFR2 and vessels counted under 403 objective (n [ 6). D. Tumour vessel
densities. *[ p< 0.05, **[ p< 0.01 compared with vector. E. LS174t cells expressing flTIA-1 were implanted into mice, and the mice treated
with either 2 mg/kg IgG (control) or 2 mg/kg anti-VEGF-A antibody bi weekly. p< 0.01 two way ANOVA. F. Vector transfected (wild type, WT)
or TIA-1 expressing cells were implanted into mice and treated with 2 mg/kg Anti-VEGF-A antibody twice per week. G. WT LS174t cells were
treated with control or anti-VEGF-A antibody biweekly. Tumour volumes were measured by calliper. P< 0.05 two way ANOVA. **[ p< 0.01,
* [ p< 0.05 compared with control, Bonferroni post hoc test.
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those expressing sTIA-1, and were more resistant to anti-
VEGF antibodies such as bevacizumab. These results indicate
that K-ras mediated splicing of an RNA binding protein may
regulate isoform specific expression of VEGF, providing an
added layer of complexity to the angiogenic profile of colo-
rectal cancer and their resistance to anti-angiogenic therapy.
This opens up the question as to what is the downstream
mechanism through which K-Ras regulates TIA-1 splicing.
There is no clear evidence as to how K-Ras activation can
induce splicing switches. Splicing is regulated by the complex
interaction of splicing factor proteins that can be phosphory-
lated, localise to the nucleus and take part in a complicated
interaction with other RNA binding proteins and auxillary fac-
tors that control splice site location. Themechanisms through
which TIA-1 is spliced is not known, and none of the known
splicing factors have yet been identified as controlling Exon
6A splicing. Interestingly, over-expression of human flTIA-1
did not induce sTIA-1 splicing in cancer cells, in contrast to
that shown by mouse flYIA-1 in human HEK cells (Le Guiner
et al., 2001).The finding that over-expression of VEGF-A165 can reverse
the effect of flTIA-1 expression on tumour growth inhibition
suggests that the effect was VEGF splicing dependent, through
anti-angiogenic activity, or through direct effects on the cells.
These findings may have significant therapeutic implications,
but are not directly translatable. Low VEGF-A165b levels pre-
dict bevacizumab response in CRC (Bates et al., 2012), but, bev-
acizumab provides significant clinical benefit in patients
irrespective of K-rasmutations (Hurwitz et al., 2009). Although
patients with K-ras mutations did do better on bevacizumab
comparedwith controls (9.3 comparedwith 5.5months, an in-
crease of 3.8 months), they did not perform as well as patients
with wild type K-ras (13.5 versus 7.4, an increase of 6.1
months). It would therefore be interesting to know how pa-
tients with K-ras mutations, in which sTIA-1 is expressed,
responded. It is not yet clear whether sTIA-1 predicts survival,
or can drive angiogenesis by reducing the anti-angiogenic
VEGF-A165b splice variants, or by increasing the VEGF-A165
variant. These VEGF-A165b variants have been shown to be
down regulated so far in melanoma (Pritchard-Jones et al.,
2007), colon (Varey et al., 2008), prostate (Woolard et al.,
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 6 7e1 7 8 1772004), and kidney (Bates et al., 2002) cancers, but the mecha-
nism of regulation of these variants in cancer is still poorly
described (Amin et al., 2011; Nowak et al., 2010, 2008). The
loose relationship between sTIA-1 and VEGF-A165b down regu-
lation in patients suggests a complex interaction, just as for
alternative splicing of p73 and VEGF-A165b isoforms, also
demonstrated in colon cancer (Diaz et al., 2008). This is sup-
ported by the findings that Ras inhibition in 10C cells was
more effective at lower doses than in LS174t cells, and that
the RNA and protein levels of VEGF-A165b in the presence or
absence of shTIA-1 are not directly correlated. The effect of
TIA-1 on RNA stability, as shown in Figure 3 indicates that
TIA-1 is likely to act in a pleiotropic manner on the amount
of VEGF isoforms present e acting by altering translation spe-
cifically for one set of isoforms, by regulating splicing at the
proximal splice site, or, most likely, by changing both splicing
and translation. Binding of TIA-1 to the VEGF RNAwas shown,
but it is also possible that other vascular growth factors are
regulated by TIA-1, although these have not yet been
published.
In summary, we show that alternative splicing of TIA-1 in
human colon cancer may regulate the balance of the pro-
and anti-angiogenic VEGF-A isoforms, and control tumour
growth and angiogenesis in animal models. This suggests
that TIA-1 can act as a splicing and translational regulator of
VEGF-A and alternative splicing of TIA-1 may lead to
enhanced angiogenesis and tumour growth in colorectal can-
cer, and resistance to anti-VEGF-A therapy.Contributions
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